SST and ovarian carcinoma: Based on these data, it is possible that, in the future, chimeric compounds combining somatostatin with other compatible hormones, could be used, especially in the case of multi-hormone-dependent tumors, such as breast cancer and prostate cancer [476] and ovarian cancer [477,478].